Disease modifying agent | Adverse events |
---|---|
Interferon beta | • Depression |
• thrombotic microangiopathy | |
• hepatotoxicity | |
• ISRs | |
• Flu-like | |
• LFT elevation | |
• Leukopenia | |
Glatiramer acetate | • ISRs |
• Benign systemic reaction | |
Mitoxantrone | • Cardiac toxicity |
• Leukemia | |
Natalizumab | • Infusion reactions |
• PML | |
• Infusion-related fatigue | |
Fingolimod | • Bradyarrhythmia |
• Macular edema | |
• Herpes virus infection | |
• PML | |
• BCC | |
• LFT elevation | |
• Lymphopenia | |
• Mild hypertension | |
Teriflunomide | • Hepatotoxicity |
• Peripheral neuropathy | |
• Alopecia | |
• Nausea/Diarrhea | |
Dimethyl fumarate | • Flushing |
• Gastrointestinal | |
• PML | |
Alemtuzumab | • Infusion reactions |
• ITP | |
• Goodpasture syndrome | |
• Thyroid cancer | |
• Infections | |
• Autoimmune thyroid disease |